CLCGY:OTC-Clicks Group Ltd (USD)

COMMON STOCK | Pharmaceutical Retailers |

Last Closing

USD 43.2

Change

-0.88 (-2.00)%

Market Cap

USD 5.54B

Volume

500.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Clicks Group Limited, together with its subsidiaries, operates as a health, wellness, and beauty retailer in South Africa and internationally. It operates through two segments: Retail and Distribution. The company retails pharmacy, health, and beauty through stores, and in-store pharmacies for the middle to upper income markets under the Clicks brand name. It also offers various range of mother and baby products including baby hardware, accessories, health, foods, diapers and wipes, and baby toiletries under the Clicks Baby brand; beauty therapy, grooming, and ethnic hair care under the Sorbet brand name; diabetic clinic, travel clinic, and wounds management practice under the M-KEM brand; and naturally-inspired beauty products under The Body Shop brand name. In addition, the company involved in the wholesale and supply of pharmaceutical products to retail pharmacies, private hospitals, dispensing doctors, and retail health stores under the UPD brand. The company was formerly known as New Clicks Holdings Limited and changed its name to Clicks Group Limited in June 2009. Clicks Group Limited was founded in 1968 and is headquartered in Cape Town, South Africa.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-04 )

Largest Industry Peers for Pharmaceutical Retailers

Symbol Name Price(Change) Market Cap
JDHIY JD Health International Inc

N/A

USD 10.21B
JDHIF JD Health International Inc

N/A

USD 9.97B
ALBHF Alibaba Health Information Tec..

+0.01 (+0.85%)

USD 8.52B
RADLY Raia Drogasil SA ADR

-0.39 (-7.65%)

USD 8.40B
SAEYY Shop Apotheke Europe N.V

N/A

USD 2.98B
SHPPF Shop Apotheke Europe N.V

N/A

USD 2.67B
ZRSEF Zur Rose Group AG

N/A

USD 0.68B
NOTR Nowtransit Inc

N/A

USD 0.55B
NVACF Nova Cannabis Inc

N/A

USD 0.08B
RXMD Progressive Care Inc

N/A

USD 0.01B

ETFs Containing CLCGY

N/A

Market Performance

  Market Performance vs. Industry/Classification (Pharmaceutical Retailers) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 21.86% 76% C+ 73% C
Dividend Return 2.13% 100% F 33% F
Total Return 23.99% 76% C+ 72% C
Trailing 12 Months  
Capital Gain 61.19% 78% C+ 86% B+
Dividend Return 2.82% 100% F 40% F
Total Return 64.01% 78% C+ 85% B
Trailing 5 Years  
Capital Gain 50.37% 87% B+ 78% C+
Dividend Return 10.35% 100% F 35% F
Total Return 60.71% 87% B+ 77% C+
Average Annual (5 Year Horizon)  
Capital Gain 4.96% N/A N/A 47% F
Dividend Return 6.96% N/A N/A 46% F
Total Return 2.00% N/A N/A 41% F
Risk Return Profile  
Volatility (Standard Deviation) 23.73% N/A N/A 81% B-
Risk Adjusted Return 29.33% N/A N/A 65% D
Market Capitalization 5.54B 82% B 86% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector